Results 221 to 230 of about 35,844 (248)

A randomised Phase 3 study comparing the efficacy and safety of proposed denosumab biosimilar RGB-14-P and reference denosumab in women with postmenopausal osteoporosis. [PDF]

Osteoporos Int
Seefried L, Ferrari S, Páll D, Viapiana O, Rosa J, Supronik J, Licheva RN, Kiefer J, Jeszenői N, Horvát-Karajz K, Jókai E, Takács I.   +11 more
europepmc   +1 more source

A predictive nomogram for treatment response in osteonecrosis patients receiving denosumab with UKA: integrating bone turnover markers and functional parameters. [PDF]

Endocr Connect
Zou G, Pu K, Zeng Y, Liu L, Chen R.
europepmc   +1 more source

Efficacy and safety of denosumab in treatment of osteoporosis in patients with rheumatoid arthritis: a meta-analysis and systematic review. [PDF]

BMC Musculoskelet Disord
Zhang R, Kou N, Liu F, Zhou H, Ren L.
europepmc   +1 more source

Transient increase in skeletal-related events after discontinuation of high-dose denosumab in cancer patients. [PDF]

J Bone Oncol
Setsu N, Yokoyama N, Esaki T, Yamaguchi M, Tokunaga E, Negishi T.   +5 more
europepmc   +1 more source

Effectiveness and safety of denosumab monotherapy in patients with primary hyperparathyroidism: A retrospective study. [PDF]

Medicine (Baltimore)
Okada A, Baba R, Ishibashi Y, Otagaki Y, Kodama T, Egusa G, Nagano G, Matsuda T, Hattori N, Ohno H.   +9 more
europepmc   +1 more source

How does denosumab compare to bisphosphonates for the prevention of skeletal-related events in cancer patients with bone metastases?

Tripdatabase
openalex   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone

Nature Reviews Rheumatology, 2023
Serge Ferrari
exaly  

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Lancet, The, 2011
Janet E Brown, Lawrence I Karsh, Piotr Milecki   +2 more
exaly